Bruker Corporation (BRKR) To Go Ex-Dividend on March 23rd

Bruker Corporation (NASDAQ:BRKR) announced a quarterly dividend on Thursday, February 19th. Stockholders of record on Monday, March 23rd will be paid a dividend of 0.05 per share by the medical research company on Tuesday, April 7th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, March 23rd.

Bruker has raised its dividend payment by an average of 0.0%annually over the last three years. Bruker has a dividend payout ratio of 7.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Bruker to earn $3.15 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 6.3%.

Bruker Price Performance

BRKR opened at $33.33 on Friday. Bruker has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a 50 day moving average of $41.57 and a two-hundred day moving average of $41.00. The company has a market cap of $5.07 billion, a P/E ratio of -222.17, a P/E/G ratio of 2.01 and a beta of 1.19. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts expect that Bruker will post 2.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Guggenheim lifted their price target on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Bank of America increased their target price on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. Finally, Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.